



 **International
Myeloma Society**

**PROGRAMS &
INITIATIVES**





Vision Statement

To cure myeloma by fostering research, education, and excellence in clinical care worldwide.

Mission Statement

The International Myeloma Society (IMS) promotes education, research, and clinical care globally by:


- Building a global myeloma community
- Educating for today and the future
- Fostering clinical and translational research in myeloma
- Assuring clinical excellence worldwide



Our Membership

The International Myeloma Society has over 1,000 members in 58 countries. All Physicians and Researchers with an interest in myeloma are invited to become members.

Trainees can apply to be members-in-training at a special rate. Industry representatives and allied health professionals are welcome to become associate members. There is also a special member tier for members in Low- and Middle-Income Countries.



Membership Benefits

You are invited to become a member of the International Myeloma Society. IMS membership entitles individual members to sponsor one abstract at each IMS Meeting. Other membership privileges and benefits include:

- A copy of the abstract and education book produced for the International Myeloma Society Annual Meeting.
- Discounted registration fees for the IMS Annual Meeting and other IMS-sponsored events
- Free online subscription to the journal *Clinical Lymphoma, Myeloma & Leukemia*
- Opportunity to be an effective voice for myeloma advocacy
- Eligible to be a candidate for Board of Directors, Subcommittees, Awards, and Travel Grants
- Participation in the nomination and election process
- Access to slides from the Annual Meeting and other myeloma meetings

Our Leadership



Philippe Moreau
President



Shaji Kumar
Vice President



Noopur Raje
Secretary



María-Victoria Mateos
Treasurer



Nikhil Munshi
Immediate Past President



Jesús San Miguel
Past President



Kenneth Anderson
Past President

Board Members



Masahiro Abe



Dorotea Fantl



Francesca Gay



Sundar Jagannath



Pankaj Malhotra



Saad Usmani



Elena Zamagni

EDUCATIONAL PROGRAMS

IMS Annual Meeting

The International Myeloma Society Annual Meeting is the leading annual meeting in myeloma, focusing on basic, preclinical, and clinical aspects of multiple myeloma and related plasma cell disorders.

The IMS Annual Meetings feature presentations from more than 150 Key Opinion Leaders who serve as members of our faculty. Abstracts, posters, joint symposia, keynotes, meet-the-expert sessions, career development workshops, roundtable discussions, and more are offered each year.






Future editions of the meeting have been scheduled:

- 22nd Annual Meeting: Toronto, Canada September 17-20, 2025
- 23rd Annual Meeting: Glasgow, Scotland September 23-26, 2026
- 24th Annual Meeting: New Delhi, India Sept. 29-Oct. 2, 2027

Attendance Data



Educational Programs

One of the most important goals of IMS is to provide clinically focused education to practicing oncologists worldwide. The IMS accomplishes this mission by providing educational forums in the form of workshops conducted around the globe.



The goal for the Educational Workshop is to share with local hematologists state-of-the-art methods in diagnosis, monitoring, and treatment of plasma cell malignancies with a focus on loco-regional current practices and opportunities for improvement. The workshops also offer the opportunity to establish potential collaborations with the invited speakers, including the possibility of visiting local institutions or establishing fellowship programs.

The program includes lectures plus roundtable discussions on the hottest and most controversial topics and case presentations to supplement didactic education. The format of the roundtable includes a point-counterpoint debate among the invited speakers and local hematologists, based on challenging practice-based questions and clinical cases. Past programs have taken place in various locations across the globe, including the United States, Chile, Greece, Brazil, Spain, Germany, the Czech Republic, and Argentina.

Upcoming Programs:


- Educational Workshop: Johannesburg - January 17-18, 2025
- Educational Workshop: Marrakech, Morocco – April 25-26, 2025
- Educational Webinars in the United States:
 - NDMM East Coast – April 2, 2025
 - NDMM West Coast – April 9, 2025
 - RRMM East Coast – October 8, 2025
 - RRMM West Coast – October 15, 2025

IMSOUND is a new audio series developed and produced by the International Myeloma Society. In this series, Key Opinion Leaders are invited to give short presentations about hot button issues facing the global myeloma community.

The first series of IMSOUND, recorded May-July 2024, is available online now. Topics explored in the first series include: Patient-reported symptoms and health-related quality of life outcomes in myeloma drug approvals; prevention of infection with immune-based myeloma therapies; the Spanish experience of developing an academic CAR-T; myeloma drug access in Brazil; European point of view on optimal therapy for young myeloma patients; role of PET-CT in response assessment; findings from myeloma registries in Australia and New Zealand; resistance to bispecific antibodies; tandem stem cell transplants; and ongoing Nordic myeloma clinical trials.

Workshop on Immune Effector Cell Therapies in Multiple Myeloma

Since 2019, the International Myeloma Society has hosted an annual Immune Effector Cell Therapies in Multiple Myeloma Workshop to discuss various immune-based therapies in myeloma, including updated clinical data for CAR T-cells and bispecific antibodies/ T-cell engagers and promising preclinical leads on novel therapies/targets. In the workshop, myeloma experts also review the latest evidence on best practices for managing toxicities associated with immune-based therapies, mechanisms of resistance, and strategies for improving/enhancing T-cell therapeutic benefits. This year's workshop also included a session on expanding access to T-cell therapies. A report based on this session is being developed for publication later in 2024.



The 6th Annual Immune Effector Cell Therapies Workshop is scheduled for March 28-29, 2025 in Boston, Massachusetts.


Workshop on Response Criteria in Multiple Myeloma

As myeloma therapies continue to evolve, it is important for response criteria and categories of response among patients receiving anti-myeloma therapies to be re-evaluated and revised. The consensus criteria for response and minimal residual disease (MRD) assessment in multiple myeloma were mostly recently updated in 2016. With the addition of several novel therapies and combination regimens and considering the evolving significance of MRD in myeloma clinical studies and routine practice, the IMS has planned a meeting to discuss response criteria in myeloma in the contemporary era.

The Response Criteria Workshop will be an invitation-only event held in Paris, France, on November 16-17, 2024. The workshop will explore key aspects of response assessment in myeloma, including M-protein evaluation, bone marrow testing methods and thresholds, role of peripheral blood testing and imaging, and response assessment approaches across the continuum from smoldering myeloma to relapsed/refractory disease. A manuscript will be developed based on the discussions at the workshop.

Workshop on Genomics – Genomics and translational medicine in myeloma

In 2023, the IMS hosted the first of a planned series of annual meetings on Genomics. These two-day meetings will take place in Europe and will be co-hosted by key thought leaders in myeloma genomics from the United States, Spain, and France. The initial invitation-only meeting was focused on redefining high-risk myeloma in the contemporary genomics era and the resultant consensus report is slated to be published in 2024.



The second Workshop on Genomics was held in Barcelona, Spain, on July 12-13, 2024 in Europe. The meeting explored therapeutic targets in high-risk myeloma, the role of t(11;14) in myeloma risk stratification and therapeutic decision-making, and biomarker-driven therapies. The meeting also highlighted cutting-edge research and evolving concepts, including novel sequencing platforms, single-cell genomics, clonal evolution in myeloma, and epigenomic dysregulation. The third Workshop on Genomics is planned for July 2025.

Collaborations with local societies

The IMS co-sponsors meetings and workshops organized by local myeloma societies around the world. The IMS provides insights for programs, speaker suggestions, and educational content for these meetings to ensure content is free from conflict and bias. These workshops foster local participation while providing an international view on recent developments. IMS has co-sponsored meetings and symposia with local organizations in Poland, Israel, Japan, and Argentina as well as with larger groups including IFM, EHA, COMy, and DGHO, with future collaborations being planned. Throughout 2025, the IMS will co-host WebIMarS, a series of webinars on Relapsed Refractory Multiple Myeloma with local societies in Australia, Japan, the Middle East, Western Europe and the United Kingdom.




Supporting Trainees

IMS believes that supporting trainees assures the future of myeloma treatment. The Society has a designated Career Development subcommittee, focused entirely on how the IMS can support postdoctoral fellows, trainees, and other young investigators. The Career Development Award has provided over \$1.7 million in funding for young investigators to spend a year working in a lab in a different country, resulting in collaborations between institutions in different countries.

IMS also hosts special workshops for postdoctoral fellows at the annual meeting, as well as sessions in our other workshops throughout the year.

Through the Young Investigator Awards, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the Annual Meeting. Since 2019, the IMS has provided funding for over 200 young investigators from around the world to attend the IMS Annual Meeting and present their own research.



RESEARCH INITIATIVES

Funding Opportunities

International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award

PAULA &
RODGER **RINEY**
FOUNDATION

Goal: To foster and support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of plasma cell disorders. Although focused on finding a cure for multiple myeloma, the area of research is broad. This award will also encourage interaction between institutions to enhance collaborative research.

Budget: The grant will be an award between \$175,000 to \$250,000.

Research areas: Translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. Translational Research is defined in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the treatment of myeloma. Translational research projects may involve the use of any cellular, molecular, structural, biochemical, and/or genetic experimental approaches. By this definition, projects are permitted to move

not only in the forward direction, toward clinical trials and studies in areas of prevention, early detection, treatment, and development of biomarkers, but also in the reverse direction, using human biospecimens, often from clinical trials, to study new phenomena, or to develop new targets and treatments. Proposed projects must be focused on translational research that meets the definition provided above and result in clinical translation. Proposed projects must be dedicated to capitalizing on research opportunities that have the potential to change the current paradigm in the management of myeloma.



Paula and Rodger Riney

Career Development Award

Goal: To foster career development among young academic scientists pursuing research in the field of plasma cell disorders and to promote the development of the next generation of leaders in this field. This award will also encourage interaction between institutions to enhance collaborative research.



Budget: The grant will be an award of up to \$75,000 including the maximal allowable institutional overhead of 8%. This may include 1 year of salary support for the grantee, budget for visa status adjustment, and travel allowance.

Research areas: Basic and translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. Outcomes research and non-laboratory projects that do not require a stay abroad in a research laboratory do not qualify for full funding but may be considered to receive partial funding.

Through the Translational Research and Career Development Awards, **the IMS has become the largest funder of myeloma-focused research worldwide.** Since 2021, The IMS has provided more than \$12.7 million to fund 72 projects, connecting 53 institutions in 20 countries.

Applications for the 2025-2026 grant cycle will be accepted from October 2024 – January 31, 2025, with acceptances anticipated to be announced in April.

International Myeloma Study Summits

The International Myeloma Society is dedicated to facilitating conversation and discussion and, wherever possible, collaboration. Within a short time, there has been great progress in multiple myeloma with several novel therapies, as well as triplet- and quadruplet- combinations. There has been significant progress in understanding the role of MRD and evaluating other endpoints. This has led to the design and conduct of multiple clinical studies, vastly expanding clinical data on myeloma therapies. However, many clinicians and researchers may not be aware of ongoing and/or planned studies.

To raise awareness of myeloma clinical studies and associated issues, the IMS has created the International Myeloma Study Summit, a biannual gathering of leaders from large myeloma groups throughout the world. This meeting serves as an opportunity for group leaders to share the details of ongoing Phase III studies and plans, within the limits of what can be shared, so that other groups can learn from and develop their future studies to complement ongoing research without overlap.

ADVOCACY

To Stimulate Awareness and Access

Therapeutic MAP (TMAP)

The International Myeloma Society (IMS) is dedicated to providing global support and educational resources to oncologists and hematologists, to aid them in making informed treatment decisions for myeloma patients. In recent years, multiple myeloma treatment has seen significant advancements, leading to improved patient outcomes. However, the availability and access to these treatments vary greatly depending on regional approval and reimbursement policies. As a result, practice patterns differ, and patient access to treatments is inconsistent.

To address these disparities, IMS has launched the Therapeutic Map (TMAP) initiative. TMAP is a computer-based program designed to offer region-and country-specific guidelines to support hematologists and oncologists in caring for multiple myeloma patients. This program will provide crucial information on the availability and coverage of treatments in different regions.

Available Regimen

	Drug Combinations
Newly Diganosed MM	VRD,VTD,VCD, VTD-dara, Rd, Rd-dara, VMP, VMP-dara
First Relapse	rd-dara,Ixa-Rd, KRd, KD-dara, PVD, Kd, Vd, Vd-dara
Relapse: 1-3 lines	Rd-dara, Ixa-Rd, KRd, KD-dara, PVD, Kd, Vd, Vd-dara, PD, PCD, Isa-PD
Relapse: ≥ 3 lines	Rd-dara, Ixa-Rd, KRd, KD-dara, PVD, Kd, Vd, Vd-dara, PD, PCD, Isa-PD
Relapse: ≥ 4 lines	Rd-dara, Ixa-Rd, KRd, KD-dara, PVD, Kd, Vd, Vd-dara, PD, PCD, Isa-PD

The TMAP steering committee comprises 16 myeloma experts from nine countries, ensuring a diverse and comprehensive approach. Data collection is actively ongoing in select countries, and the map’s development is progressing steadily. The anticipated launch of TMAP is scheduled for mid to late 2024.

The IMS has partnered with HealthTree, a global nonprofit organization dedicated to supporting patients diagnosed with blood cancers and their families, on a three-year survey on bispecific antibody-based therapies.

The IMS has also formed a TMAP data partnership with the Myeloma Patient Europe (MPE), an organization linking multiple myeloma/AL amyloidosis patient support organizations across 33 countries.

Available Agents

	Drug Combinations
Newly Diganosed MM	Bortezomib, lenalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab
First Relapse	Bortezomib, carfilzomib, , lenalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab, isatuximab
Relapse: 1-3 lines	Bortezomib, carfilzomib, ixazomib, lenalidomide, pomalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab, isatuximab
Relapse: ≥ 3 lines	Bortezomib, carfilzomib, ixazomib, lenalidomide, pomalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab, isatuximab
Relapse: ≥ 4 lines	Belatamab, selinexor, melflufen, idecel

Regulatory Relationships

The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. However, relapses are common and there is a continued need for safer, more effective therapies. To identify opportunities for facilitating future drug development of novel therapies in multiple myeloma and improving patient outcomes, current paradigms in the study and conduct of myeloma clinical studies and the implications for regulatory approval and availability of newer therapies need to be discussed and re-evaluated.

On November 8-9, 2022, the IMS hosted the first joint symposium with the FDA, which provided a forum for open discussion among academia, industry, and regulatory agencies about clinical drug development in multiple myeloma. The 2022 IMS-FDA Joint Workshop—*“Future of Drug Development in Multiple Myeloma”*—focused on trial design, patient population, and endpoints in different multiple myeloma disease settings.

On February 22, 2024, the IMS held another joint workshop with the FDA. The second IMS-FDA Joint workshop—*“Defining Patient Populations for Clinical Studies in Multiple Myeloma”*—focused on identifying challenges and formulating potential solutions for clinical development of novel myeloma therapies in the contemporary era of triplet or quadruplet upfront treatments and innovative T-cell-directed immunotherapies. These meetings enable stakeholders, including myeloma experts, academicians, and clinicians, as well as patient advocates and representatives of the pharmaceutical industry and government agencies, to participate and engage in finding optimal pathways for myeloma drug development. Manuscripts based on the discussions at the IMS-FDA Joint Workshops have been developed for publication.

Future IMS-FDA joint meetings are currently in the planning stages. In addition, regulatory sessions will also be held at the 2024 IMS Annual Meeting in Rio de Janeiro, Brazil.

IMS/EMA Collaborative Initiative

The IMS is building a relationship with EMA based on the success of our past joint workshops with the FDA. An invitation-only 2024 IMS-EMA Joint Workshop will be held on October 18, 2024, in Paris, France. The meeting will focus on MRD as an endpoint in myeloma trials, role of real-world evidence, and dose adaptation of myeloma therapies.



IMS AWARDS

Waldenström Lifetime Achievement Award

Named for Jan Waldenström, a pioneer in treating blood cancers, the Waldenström Lifetime Achievement Award has been given by the IMS at each International Myeloma Workshop since 1989. This award is given to outstanding researchers in recognition of their long term contributions to the myeloma field.

Past Recipients

- 1989 – D. Bergsagel
- 1991 – R. Kyle
- 1993 – S. Salmon
- 1995 – M. Potter
- 1997 – R. Alexanian
- 1999 – B. Barlogie
- 2001 – H. Mellstedt
- 2003 – K. Anderson
- 2005 – J-L Harousseau
- 2007 – J. San Miguel
- 2009 – B. Durie
- 2011 – W. M. Kuehl
- 2013 – N. Munshi
- 2015 – M. Attal
- 2017 – M. A. Dimopoulos
- 2019 – G. Merlini
- 2021 – S. V. Rajkumar
- 2022 – P. Sonneveld
- 2023 – S. Jagannath
- 2024 – T. Facon



The Bart Barlogie Clinical Investigator Award

In recognition of the outstanding research led by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Clinical Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research.

The Bart Barlogie Clinical Investigator Award will be given to an investigator in recognition of their research in the myeloma field.

Past Recipients

- 2015 – B. Paiva
- 2017 – G. Palladini
- 2019 – F. Gay
- 2021 – S. Usmani
- 2022 – M-V. Mateos
- 2023 – S. Kumar
- 2024 – S. Lonial

Ken Anderson Basic and Translational Research Award

Established by IMS to honor the seminal contributions of Professor Ken Anderson for his bench to bedside translational research, the Ken Anderson Basic and Translational Research Award will be given to an investigator to recognize excellence in translational research in myeloma.

Past Recipients

- 2017 – I. Ghobrial
- 2019 – C. Mitsiades
- 2021 – E. P. Neri
- 2022 – N. Raje
- 2023 – H. Avet-Loiseau
- 2024 – H. Einsele





Coming Soon:



by the International Myeloma Society

Analytic Research and daTa Exchange
for Myeloma International Studies



International
Myeloma Society

www.myelomasociety.org